Sodium zirconium cyclosilicate in hyperkalemia

David K. Packham, Henrik S. Rasmussen, Philip T. Lavin, Mohamed A. El-Shahawy, Simon D. Roger, Geoffrey Block, Wajeh Qunibi, Pablo Pergola, Bhupinder Singh

Research output: Contribution to journalArticlepeer-review

235 Scopus citations

Abstract

Background Hyperkalemia (serum potassium level, +ACY-gt;5.0 mmol per liter) is associated with increased mortality among patients with heart failure, chronic kidney disease, or diabetes. We investigated whether sodium zirconium cyclosilicate (ZS-9), a novel selective cation exchanger, could lower serum potassium levels in patients with hyperkalemia. Methods In this multicenter, two-stage, double-blind, phase 3 trial, we randomly assigned 753 patients with hyperkalemia to receive either ZS-9 (at a dose of 1.25 g, 2.5 g, 5 g, or 10 g) or placebo three times daily for 48 hours. Patients with normokalemia (serum potassium level, 3.5 to 4.9 mmol per liter) at 48 hours were randomly assigned to receive either ZS-9 or placebo once daily on days 3 to 14 (maintenance phase). The primary end point was the exponential rate of change in the mean serum potassium level at 48 hours. Results At 48 hours, the mean serum potassium level had decreased from 5.3 mmol per liter at baseline to 4.9 mmol per liter in the group of patients who received 2.5 g of ZS-9, 4.8 mmol per liter in the 5-g group, and 4.6 mmol per liter in the 10-g group, for mean reductions of 0.5, 0.5, and 0.7 mmol per liter, respectively (P+ACY-lt;0.001 for all comparisons) and to 5.1 mmol per liter in the 1.25-g group and the placebo group (mean reduction, 0.3 mmol per liter). In patients who received 5 g of ZS-9 and those who received 10 g of ZS-9, serum potassium levels were maintained at 4.7 mmol per liter and 4.5 mmol per liter, respectively, during the maintenance phase, as compared with a level of more than 5.0 mmol per liter in the placebo group (P+ACY-lt;0.01 for all comparisons). Rates of adverse events were similar in the ZS-9 group and the placebo group (12.9+ACU-And 10.8+ACU-, respectively, in the initial phase; 25.1+ACU-And 24.5+ACU-, respectively, in the maintenance phase). Diarrhea was the most common complication in the two study groups. Conclusions Patients with hyperkalemia who received ZS-9, as compared with those who received placebo, had a significant reduction in potassium levels at 48 hours, with normokalemia maintained during 12 days of maintenance therapy. Copyright + 2014 Massachusetts Medical Society.

Original languageEnglish (US)
Pages (from-to)222-231
Number of pages10
JournalNew England Journal of Medicine
Volume372
Issue number3
DOIs
StatePublished - Jan 15 2015

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Sodium zirconium cyclosilicate in hyperkalemia'. Together they form a unique fingerprint.

Cite this